Company news

Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A (SSE:600196) news

Every Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updat...

Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A (SSE:600196) news

Press releases & updates

Fosun Pharma Announces 2026 Interim Results

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress in Providing Guarantee for Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Receipt of Drug Registration Approval by a Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Completion of Private Investment Fund Filing for the Investment Fund Est...

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Controlled Subsidiary's Drug Obtaining Approval for Clinical Trial

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Release of Pledge of Certain Shares of Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Implementation of A-Share Dividend Distribution for 2025

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Pledge of Partial Shares Held by a Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress in Providing Guarantee for Holding Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Resolutions of the 33rd (Extraordinary) Meeting of the 10th Board of Dir...

Announcement on Progress in Transfer of Partnership Interests and Progress in Private Equity Investment Fund Invested by the Partnership

Indicative Announcement on Obtaining EU Approval of a New Indication for a Drug Developed by the Holding Subsidiary

Announcement on Progress in Providing Guarantee for Holding Subsidiary

Announcement on Holding Subsidiary's Passing GMP Compliance Inspection

Announcement on Resolutions of the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareh...

Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary

Indicative Announcement on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share ...

Announcement on Obtaining Approval of Drug Registration by the Holding Subsidiary

Announcement on Progress in Participating in Setting up Private Equity Investment Fund

Announcement on Outward Investment and Related Party Transactions

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial

Announcement on Acceptance of Drug Registration Application of Holding Subsidiary

Notice on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Mee...

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial from FDA

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased ...

Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework

Announcement on Progress in Participation in Establishing a Private Equity Investment Fund and Proposed Disposal of Assets

Announcement on the Pledge of Partial Shares Held by Shareholders

Announcement on Approval of Supplementary Drug Application by Holding Subsidiary

Announcement on Change of Chief Financial Officer

Announcement on Participating in Setting up Private Equity Investment Fund

Announcement on Proposed Expansion of Financial Leasing Business by a Holding Subsidiary

Announcement on Resolutions of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the ...

Self-Inspection Report on Trading of the Company's Shares by Insiders Related to the Spin-off and Listing of a Subsidiary on the Main Boa...

Indicative Announcement on Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st...

Announcement on Progress in Signing the Licensing Agreement of Wholly-owned Subsidiary

Announcement on Signing License Agreement by Holding Subsidiary

Notice of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share Gene...

Announcement on Completion of Issuance of the 2026 Phase I Science and Technology Innovation Bonds

Announcement on Resolutions of the 23rd (Extraordinary) Meeting of the 10th Board of Directors

Announcement on Pledge and Release of Pledge of Partial Shares of Shareholder

Announcement on Resolutions of the 22nd (Extraordinary) Meeting of the 10th Board of Directors

Announcement on Completion of Filing with China Securities Regulatory Commission for Application for Full Circulation of Domestic Unliste...

Announcement on Progress in Implementation of the Incentive Plan by a Holding Subsidiary

Announcement on Completing Private Investment Fund Filing for Subscribed Equity Investment Fund

Announcement on Progress in Participating in the Establishment of Private Equity Investment Fund

Announcement on Holding Subsidiary's Progress in Drug Clinical Trials

Announcement on Completion of 2022 Non-public Offering Funded Projects and Closure of Special Accounts

Announcement on Reply to Shanghai Stock Exchange's "Letter of Regulation in Outward Investment"

Announcement on Signing Cooperation and Option Agreement by Holding Subsidiary